You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Carbon Nanotube-Mediated Gene Transfer into Human T-cells for CAR-T HIV Therapy

    SBC: Advanced Gene Transfer Company, Inc.            Topic: 105

    ABSTRACT The HIV pandemic has caused an estimated 33 million deaths to date. In the U.S. alone, 1.2 million people currently live with HIV and 34,800 new cases were diagnosed in 2019. This adds up to an estimated $16.4 billion for a lifetime of HIV treatment for patients in the U.S. HIV infects immune cells which express the CD4 and CXCR4/CCR5 co-receptors including helper T-cells. Even after a pa ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Chimeric antigen receptor-modified iNKT cell therapy for CD7+ malignancies

    SBC: Akeso Therapeutics Inc            Topic: 102

    PROJECT SUMMARY/ABSTRACTThe major hurdle in developing chimeric antigen receptor (CAR)-T therapy for T-cell malignancies is CAR-T cell fratricide by self-killing, which leads to insufficient numbers of CAR-T cells for infusion. CRISPR- mediated genomic editing provides an alternative approach to enabling expansion of CAR transduced T cells from allogeneic healthy donors. However, the safety and cl ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of B8C1ad as an Orphan Drug for Iatrogenic Botulism

    SBC: Cytodel, Inc.            Topic: 107

    Abstract Botulinum neurotoxin serotype A1 (BoNT/A1) has become an important therapeutic tool for multiple indications, despite being the most toxic protein known to science. Although serious Adverse Events (AEs) are rare, their importance is recognized by the Black Box warning included in the labeling for all FDA-approved BoNT/A1 products. During a recent 3-year period FDA received 13,087 AE repor ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. BoostPrime, A Novel Digital Therapeutic for Craving Mitigation in OUD

    SBC: NXTECH INC            Topic: NIDA

    PROJECT SUMMARY The National Institute on Drug Abuse indicates that “there are more deaths, illness, and disabilities from substance use than from any other preventable health condition.” In SUDs, and particularly opioid use disorder (OUD), individuals frequently experience uncontrolled craving symptoms, even receiving treatment under a supervised medication for OUD program (MOUD, also known a ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Perform non-GLP and GLP TOX/TK studies, and file a novel drug IND with the FDA for advanced pancreatic cancer patient clinical trials

    SBC: CANGET BIOTEKPHARMA, LLC            Topic: 102

    Abstract/Summary The goals of this SBIR Phase I grant are: (1) to use the clinically compatible FL118 product to perform the non- good laboratory practice (GLP) and GLP toxicology (TOX) and toxicokinetics (TK) studies; and (2) to author and file the FL118 Investigational New Drug (IND) application with the FDA for first-in-human FL118 phase 1 clinical trials in patients with advanced pancreatic du ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. USE OF DYRK1A/B KINASE INHIBITORS FOR THE TREATMENT OF LIVER DISEASES

    SBC: Avanti Biosciences Inc            Topic: 300

    PROJECT SUMMARYNonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease. One-fourth of the adult population suffers from NAFLD worldwide. Nonalcoholic steatohepatitis (NASH), the aggressive form of NAFLD, can progress to cirrhosis and hepatocellular cancer (HCC) and is rapidly becoming the leading cause of end-stage liver disease and liver transplantation. Liver fibrosi ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Mission Empower

    SBC: ROCK BY ROCK LLC            Topic: NIGMS

    Project Summary: Mission Empower: Health According to the Society of Public Health Education, only 7.5% of K-5 schools nationally provide sufficient health education (Society for Public Health Education, 2017). IDM and game-based learning strategies have the potential to help close this gap but, to date, most public health solutions have not been scalable (Zamboni, et al 2019). Too often IDM and h ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Innovative Sorbents for Stabilizing Per- and Polyfluoroalky Substances (PFAS) in Soil Contaminated by Aqueous Film-forming Foam (AFFF)

    SBC: Regenerative Solutions, Inc.            Topic: NIEHS

    Project Summary/Abstract: Per- and polyfluoroalkyl substances (PFAS) are a group of chemicals consisting of thousands of synthetic organic compounds in which the hydrogen atoms bound to the carbon backbones are fully or partially substituted with fluorine. Due to their widespread use, PFAS are detected ubiquitously. Owing to the nature of PFAS being persistent, bioaccumulative, and toxic, cleaning ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter

    SBC: Halomine Inc.            Topic: 400

    Abstract: Catheter-associated urinary tract infection (CAUTI) is the most common type of healthcare-associated infection, however currently there is no effective technology to address the problem. Antimicrobial (anti-biofilm) functionality on the catheter surface is an important field that has gained a lot of attention; however, commercial applications are limited due to a lack of infection contro ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a targeted TGF-b therapeutic that selectively blocks lung fibrosis in idiopathic pulmonary fibrosis (IPF) patients

    SBC: Synthis Therapeutics, Inc.            Topic: NHLBI

    Synthis Project Summary/Abstract Phase I NHLBIIPF is a chronic, irreversible fibrotic lung disease driven by repeated injury, resulting in progressive stiffening and ultimately, loss of lung function. With 130,000 IPF patients annually and a 5 year mortality rate of 80%, there is significant need for new therapies. To date, conventional therapies have not halted disease progression. Recently 2 new ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government